by Louiza | Jan 19, 2023 | News
PRESS RELEASE Amsterdam, The Netherlands, 19 January 2023 Annogen to develop multiple CNS-cell specific promoters for VectorY programs VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative...
by Louiza | Dec 13, 2022 | News
PRESS RELEASE Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery. AMSTERDAM, 13 December 2022 — Annogen, the Amsterdam based biotech company behind the SuRE™ technology for...
by Louiza | Jun 25, 2022 | News
Identify favorable gene insertions and their expression levels (> 100,000 integrations in parallel) Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its...
by Louiza | Feb 1, 2022 | News
Researchers aim to pinpoint non-gene components in DNA linked to production and welfare traits in cattle, gaining insights across species. Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical...
by Louiza | Jan 1, 2022 | News
Many diseases are determined by differences in yet undiscovered gene regulation. Thanks to plasmids and ‘barcodes’, the SuRE assay can map this relatively easily and extensively for the entire human genome. ‘The breakthrough came from the idea of...
by Louiza | Nov 30, 2021 | News
PRESS RELEASE – for immediate release Amsterdam, 30 November 2021 Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding...
